Fabry disease market is expected to reach USD 3.4 billion by 2030 at CAGR of 7.8% over the figure period 2022-2030. Fabry infection is an uncommon acquired problem that happens because of the development of globotriaosylceramide in the body's cells. The sickness influences people, yet men are generally more seriously impacted. As indicated by the new information recommended by the National Institute of Health, Fabry sickness affects almost 1 of every 40,000 to 60,000 guys.
Broad, innovative work exercises are key variables driving the Fabry illness market. On May 30, 2018, Amicus Therapeutics sent off Galafold containers 123mg to treat patients aged 16 years and more seasoned with an affirmed determination of Fabry illness and who have a manageable change. Likewise, Galafold is the solitary oral accuracy medication for Fabry illness in Japan.
Aside from this, numerous treatment approaches are under clinical preliminaries to treat Fabry's illness. For example, Pegunigalsidase alfa by Protalix is under stage 3 clinical preliminary to treat patients impacted with Fabry infection.
Different factors like mechanical headways, creating medical care framework, and good repayment and subsidizing strategies in developed nations are likewise expected to impede the market's development.
In any case, the absence of consciousness of the infection among doctors in creating or immature nations, different scope of side effects, and different confusions can thwart the market development over the gauge time frame.
The global Fabry disease market has been segmented into type, diagnosis & treatment and end user.
The market, based on type, has been segmented into type-1 and type-2.
The market, by diagnosis & treatment, has been segmented into diagnosis and treatment. The diagnosis segment is further classified as blood test, urine test, thyroid test, lung function test, and imaging. The imaging segment includes electrocardiogram (EKG), echocardiogram, brain MRI, CT scan and others. The treatment segment is further classified as enzyme replacement therapy, gene therapy, pharmaceutical formulations containing agalsidase alfa, analgesics, anticonvulsants, nonsteroidal anti-inflammatory drugs (NSAIDs), and others.
The market, by end user, has been segmented into hospitals & clinics, diagnostic centres, research & academic institutes, and others.
The enzyme replacement therapy is anticipated to hold the largest market share as it is the most preferred therapeutic approach to stabilize the progression of the Fabry disease.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Fabry disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European Fabry Disease market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Fabry Disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Fabry Disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Amgen Inc., Amicus Therapeutics, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., AVROBIO, Inc., Idorsia Pharmaceuticals Ltd, Protalix, Sanofi, Shire, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and others are some of the key players in the global Fabry disease market.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global Fabry disease market owing to rising healthcare expenditure, increasing awareness about the condition and technological advancements in Fabry Disease. According to the National Fabry Disease Foundation, nearly 50,000 people, in the United States, are living with Fabry disease.
Europe is expected to hold the second largest position in the global Fabry disease market. The market growth in this region is attributed to the government funding and improvement in research & development activities. In European region, Replagal by Shire is one of the most preferred treatment approaches. The approved dose of Replagal is 0.2 milligrams per kilogram of body weight.
The Fabry disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing awareness about the enzyme replacement therapy and rising healthcare spending. According to the 2016 data suggested by the Ministry of Health and Family Welfare, approximate annual cost of enzyme replacement therapy in India was USD 26,334.
The Middle East & Africa are expected to hold the least share of the market due to lack of awareness about the condition.
Global Fabry Disease Market, by Type:
Global Fabry Disease Market, by Diagnosis & Treatment:
Global Fabry Disease Market, by End User:
Global Fabry Disease Market, by Region:
Global Fabry Disease Market, by Key Players:
Amicus Therapeutics got U.S. Food and Drug Administration (FDA) endorsement for the Galafold (migalastat) 123 mg cases. Galafold is an oral, accurate medication for treating grown-ups with Fabry infection.
CHIESI Farmaceutici S.p.A. got advancement and free treatment in all nations outside the U.S. for PRX-102, an analytical therapy for treating Fabry's illness from Protalix Biotherapeutics.
Amgen Inc., Amicus Therapeutics, Inc., AVROBIO, Inc., Idorsia Pharmaceuticals Ltd, Protalix, Bristol-Myers Squibb Company, GlaxoSmithKline, iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Sanofi, Shire, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd are the key players in the market
The fabry disease market has the potential to grow with 7.8% CAGR by 2030.
The fabry disease market has extensive research and development facilities which could bolster its growth.
The leading treatment therapy segment is an enzyme replacement therapy for the fabry disease market.
The Americas has the potential to score the highest for the fabry disease market.